RIGVIR®

Oncolytic Virotherapy

About Oncolytic Virotherapy

Source:  Virotherapy.eu
Oncolytic virotherapy is an effective cancer treatment using a special virus, which is capable of finding and destroying malignant tumour cells in the body. There are only three live virus-containing medication in the world and Rigvir is the first registrated and still the one and only genetically unmodified virus available worldwide.

This study looked at data from 95 clinical trials obtained solely from ClinicalTrials.gov.
It concluded:

Most of the AEs in OVT clinical trials have been common and manageable, since they are infection-related or symptoms of nausea/vomiting. Authors consider that few serious AEs solely attributable to OVT have been detected in the clinical trials. It is notable that nausea and vomiting are among the most common AEs of other anticancer therapies. Many of the medications already in use today can serve well in managing AEs induced by OVT.


RIGVIR- First oncolytic virotherapy

Source: Rigvir.com
RIGVIR® is the first approved oncolytic virotherapy. RIGVIR® is approved for the treatment of cutaneous melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of relapse and metastasis after radical surgery.

RIGVIR® has oncolytic and oncotropic properties, it selectively infects tumour cells.

Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment, which improves time to progression, overall survival and the quality of life for cancer patients. RIGVIR® is well tolerated and causes no if any serious adverse effects.


RIGVIR® – An approved Virotherapy for Cancer

Source: International Virotherapy Center

RIGVIR®  is the world’s first approved oncolytic virotherapy medicine for the treatment of melanoma, local therapy of skin and subcutaneous metastases of melanoma, prevention of relapse and metastases after surgery.

In clinical practice RIGVIR® is used for the treatment of melanoma, cancers of stomach, colorectum, pancreas, kidney, uterus, bladder, lung, prostate and several types of sarcoma.

RIGVIR® is a live, adapted, non-pathogenic and not genetically modified virus. The vial does not contain antibiotics, stimulants, potentially toxic substances.

RIGVIR® is administered intramuscularly according to personalized treatment protocols. Virotherapy is usually ambulatory and has mild if any side effects. It is important to consult a certified virotherapy specialist to achieve the best possible result.

RIGVIR® was approved in Latvia (an EU member state) in 2004 for cutaneous melanoma therapy.

This Study concluded:
Rigvir significantly prolongs survival in early-stage melanoma patients without any side effect.



Virotherapy is recognized as safe and effective cancer treatment.

Virotherapy effectiveness has been proven in many clinical studies. For example, in 2015, the medical journal Melanoma Research published a study that revealed that melanoma patients treated with virotherapy were 4 to 6 times more likely to survive than those, who did not receive virotherapy.

The study concluded:
Rigvir significantly prolongs survival in early-stage melanoma patients without any side effect.

Potential side-effects

RIGVIR® contains an adapted live enterovirus, which is oncotropic and oncolytic, non-pathogenic and non-genetically modified. RIGVIR® does not contain antibiotics, stimulants or potentially toxic substances.
RIGVIR® demonstrates an outstanding safety profile. More than 700 patients participated in RIGVIR® clinical studies. No serious adverse effects were recorded, and the most common side effect was a subfebrile temperature.

Not unlike other medicines, RIGVIR® may cause side effects. These potential side effects are short-term and do not require treatment. The most common side effect is a subfebrile temperature lasting 1-3 days.

Source: Rigvir Group

New Viral Therapy Cancer Treatment Improves Survival Rates and Makes Everyone Smile

By Susanna Sisson
Source:
EmaxHealth

A diagnosis of cancer can instill fear, anxiety and a sense of helplessness and hopelessness in those affected including friends and family. It’s a diagnosis that can take one’s breath away. I remember hearing the news that my grandmother who raised me, had cancer. The initial reaction was mind-numbing terror, shock, and simply wanting to flee. All I knew at the time was that cancer was a death sentence.

Unfortunately, 40 years later, little has changed with regard to survival rates even with “modern advances”. What was recommended then – surgery, placement of a feeding tube, chemotherapy, and radiation is still the gold standard of care today. New drugs have been developed, new types of treatments are used, and yet the long-term survival rate remains an abysmal 2.1% overall.

But there is hope and it was a serendipitous discovery in 1960 of the oncolytic properties of enterovirus by Dr. Aina Muceniece, a Latvian scientist, immunologist, and Emeritus Scientist that led to the use of a virus with minimal and manageable mild side effects in the treatment of cancer. The virus which was named Riga after the Latvian city of Riga, was tested in phase1, 2 and 3 trials. The drug containing the Riga virus is called RIGVIR.

RIGVIR contains live, natural Riga virus, a non-pathogenic, non-mutating enterovirus which was found to have immunomodulating and cytolytic or cancer destroying effects. The action of the virus is to enter and destroy the cancer cell, however, because it only enters abnormal cancer cells, there are only short term effects such as sub febrile (low) temperature, pain in the tumor, fatigue, drowsiness and dyspepsia (diarrhea). Unlike use of chemotherapy, with RIGVIR healthy tissues are not affected or damaged, and cancers are unable to become resistant. Regarding immunomodulation, because of its structure RIGVIR selectively enters and affects cells in sensitive tumors and makes them detectable by the T-cells and B-cells in the immune system which then mount an immune response. The Riga virus is not genetically modified (GM) and is not pathogenic, nor is it able to replicate in the human body. It is issued in oncology for the prevention of secondary immunodeficiency. Another benefit of RIGVIR if that the drug targets and kills cancer stem cells so the cancer does not recur or metastasize.

Dr. Ivars Kalvins, PH.D, scientist, inventor and Director of the Latvian Institute of Organic Synthesis, led the team of researchers who completed the work of Dr. Muceniece. He is 1 of 3 finalists for the European Medicine Award (2015) and is a distinguished member of the European Academy of Science. Dr. Kalvins holds 215 patents and has authored over 650 publications. [1,5]

With a smile on his face, Dr. Kalvins explained, “There is only one medicine in the world that uses a live virus to treat cancer.”

In 2015 RIGVIR was registered in Georgia and included in the Latvian national guidelines for skin cancer and melanoma treatment. According to Dr. Elitn Shapovalora, M.D., “Success rates in early stage melanoma are 90% while in late stage the survival rate is 60%. These rates are significantly higher than the typical survival rate of 9% if treated with conventional therapy.” Melanoma is considered the deadliest type of skin cancer.

While the official clinical use of RIGVIR is in the treatment of malignant melanoma, according to Dr. Kalvins, “RIGVIR has been effective in 10 other cancers including: melanoma, lung, renal, pancreatic, breast, uterine, bladder, stomach, prostate and several kinds of sarcomas.” [1] Patients from 40 countries have received the treatment. “Cancer virotherapy is one of the most promising modern cancer therapy methods. Therefore, the leading countries in the development of pharmaceutical products have largely involved in virological researches with the aim of finding the most effective and safest viruses with the ability to selectively destroy malignant cells. Nobody doubts any more that viruses are able to do it. Just like nobody doubts any more that Latvia, through RIGVIR has become the leader and, at the same time, the pioneer in virotherapy. The only question is – how much time will it take until some other viral anticancer medicines will join RIGVIR. Clearer and stronger with every day, virotherapy is claimed around the world as one of the firm primary therapy types, that can be more effective, safer, and patient-caring than the cancer treatment methods known until now. I will do everything that depends on me in order to develop virotherapy and help many cancer patients around the world, who have deserved such humane and effective treatment long ago.” [5]

Oncolytic virotherapy in the world is coordinated by the International Virotherapy Center (IVC) in Latvia. The mission of the IVC is to provide virotherapy treatment to every cancer patient who needs it. The main objectives of the IVC are training and certification of doctors, accreditation of medical institutions and coordination of international service of patients.

The cost of the RIGVIR in Georgia where is has been approved is about 1050 Lari which is about $444 USD. Rigvir® is delivered as an intramuscular injection. For those in the US, the nearest treatment center is the Hope 4 Cancer Institute in Tijuana, Mexico.

Published Clinical Trials / Studies / Reviews:

This study says:
In conclusion, Rigvir significantly prolongs survival in early-stage melanoma patients without any side effect.

This study says:
Rigvir significantly improves 3-year and 5-year survival of melanoma and cancer rectum patients.

This 2016 study says:
Using current standard treatments, the survival of patients with the present diagnoses is low. In contrast, the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been stabile for over 1.5, 6.5, and 4 years, respectively. These observations suggest that virotherapy using Rigvir can successfully be used in long‐term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV…

This 2017 study concludes:
The results suggest that Rigvir® in vitro reduces the viability of cells of human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma, pancreas adenocarcinoma …The present results suggest that the effect of Rigvir® could be tested in other cancers besides melanoma.

This study says:
These observations suggest that virotherapy using Rigvir can successfully be used in long‐term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV and therefore could be included in prospective clinical studies.

This 2018 study says:
It has been previously suggested that Rigvir® improves the overall survival in patients with stage IB–IIC melanoma. The present report describes a melanoma unknown primary brain metastasis patient treated with Rigvir® virotherapy. There are limited options to treat brain metastasis because of the brain–blood barrier. The present patient has been stabilized following Rigvir® virotherapy, suggesting that the oncolytic virus Rigvir® might have reached the brain metastasis.

Case report (2018):
In this report, we describe a female patient with unknown primary melanoma brain metastasis treated with the oncolytic ECHO-7 virus Rigvir® after brain surgery. The patient has been stable, as monitored by magnetic resonance imaging, for more than 3.8 years with ongoing therapy. The median expected overall survival from the time of diagnosis is approximately 5 months.

This 2017 study says:
Rv, a wild-type ECHO virus, represents an intriguing possibility among other oncolytic viruses in this context and has been studied mostly in Latvia. Currently, limited retrospective data from Latvia are available. Larger prospective randomized studies and evaluations by investigators outside of Latvia will allow for more rigorous assessments and future development of Rv as a cancer virotherapeutic.

More at Cancer Virotherapy

Where can I get this treatment and more information?

The nearest clinic for patients in Ireland and the UK is in Germany:

Marinus Klinik
Responsible specialist: Dr. Axel Weber

Language for communication: DE, ENG
Address: Biberstraße 30, 83098 Brannenburg, Germany
Tel.: +49 8034 9080 Fax: +49 8034 90 82 99
E-mail: info@klinik-marinus.de
Website: www.klinik-marinus.com

Global Virotherapy Cancer Clinic (Latvia)
Language for communication: ENG, RUS, LAT
Address: 12 Jauna iela, Jurmala, Latvia, LV-2015
Phone: +371 67 229 522
E-mail: clinic@virotherapyclinic.eu
Website: www.virotherapyclinic.eu

Mexico
Hope 4 Cancer Institute – Exclusive partner in Mexico
www.hope4cancer.com

Georgia
MedCenter
Website: www.medcenter.ge

Testimonials
http://www.virotherapy.eu/patient-stories.php

Warning
1. Some cancer therapies can conflict with others. Do not start ANY therapy without consulting your doctor to ensure it’s safe and beneficial to do so.
2. Just because any given therapy worked for someone else does not necessarily mean it will work for you.
3. Although there are many viable alternative cancer treatments, there isn’t a “best” treatment for a certain type or stage of cancer.

Please share to help others